Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Eli Lilly and Novo Nordisk have seen demand surpass supply of their weight loss drugs. Their revenues have soared thanks to these popular products.

Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?

GLP-1 (Semaglutide) drugs like Ozempic and Wegovy produced by Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound (Tirzepatide) produced by Eli Lilly and Co. NYSE: LLY have taken the mainstream by storm. These drugs have transformed the medical sector.

Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill

Dutch Bros

Quanta Services

Reduced interest rates make it easier for firms to buy other companies. That's because acquiring firms can borrow the money needed to finance mergers and acquisitions (M&A) deals much more cheaply when rates are low.

Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts

Viking Therapeutics' share price has rapidly increased from recent weight loss drug excitement. The company's value seems to be derived from its weight loss and NASH/MASH candidates. VK2735, the weight loss candidate, presents a potentially massively large opportunity, despite the crowded market.

Viking Therapeutics: Future Weight Loss Heavyweight?

Viking Therapeutics' pipeline looks highly promising. The biotech stock might be a millionaire-maker if its obesity and NASH drugs achieve their potential.

Could Viking Therapeutics Stock Be a Millionaire Maker?

Arcutis Biotherapeutics

Janux Therapeutics

Amylyx Pharmaceuticals

Seres Therapeutics

Rapt Therapeutics Inc

Revance Therapeutics

Forget artificial intelligence stocks like Nvidia and Super Micro Computer. Biotech stocks are doing much better this year.

VKTX, JANX and these biotech stocks are surging in 2024

Altimmune

Madrigal Pharmaceuticals

Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of retiring baby boomers, demand for better care, pharmaceutical companies nearing patent expirations, a resurgence of mergers and acquisitions, and even new treatments that'll help you shed weight.

The 3 Best Biotech Stocks to Buy in April 2024

Eiger BioPharmaceuticals

Novo Nordisk

Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.

Healthcare stocks fade as obesity-drug optimism fades

Viking Therapeutics is a clinical-stage biotechnology company developing a weight management candidate. Viking Therapeutics' weight management candidate, VK2735 is similar to the active ingredient in Eli Lilly's blockbuster weight management treatment.

Viking Therapeutics Stock Has 72% Upside, According to 1 Wall Street Analyst

Pfizer

Viking Therapeutics may be on the verge of a breakthrough obesity care treatment. Right now, obesity care and diabetes are dominated by Novo Nordisk and Eli Lilly.

Prediction: Pfizer Won't Acquire Viking Therapeutics. Here's Why.

Brookfield Renewable Partners

Procter & Gamble

Toast

Toast is a growth stock that is down but not out. Viking Therapeutics has massive upside potential.

5 Top Stocks to Buy in April

Eli Lilly

Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound, have already generated billions of dollars in revenue but this may be the tip of the iceberg. Viking Therapeutics' VK2735 has emerged as a strong contender in the GLP-1 drug market, with promising weight loss results in clinical studies.

Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data

Fluor

SoundHound AI Inc

The Russell 2000 index offers investors various small-cap companies that can incite great long-term returns and add a more differentiated investment to their portfolio. Not all stocks in the Russell 2000 are automatic wins, but there are certainly some worth keeping your eye on.

The 3 Best Russell 2000 Stocks to Buy in Q2 2024

Viking's drug candidate has shown promise in clinical studies as a potential weight loss medicine. Madrigal just launched the first (and so far only) medicine approved by the U.S. for NASH.

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals

The biotech concluded an encouraging early-stage trial of its weight-loss drug candidate. It successfully tested a tablet version of the treatment.

Why Viking Therapeutics Stock Was Rocketing Higher This Week

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market in 2022, and investor preference for big tech stocks have meant underperformance for biotech stocks.

2 Top Biotech Buyout Candidates

Amgen

Rhythm Pharmaceuticals

The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.  Pharmaceutical companies are answering the urgent need for effective solutions with a new generation of weight loss drugs capable of achieving previously unattainable levels of weight reduction.

7 Stocks That Will Drive the Weight Loss Drugs Market

Boeing

MicroStrategy Incorporated

Despite the general fears that the retaining of high interest rates could spark a recession and severely damage the stock market, the situation has been the opposite for the most part in 2024.

3 stocks to turn $100 into $1,000 in April

Viking's impressive gains are due to excitement about its experimental obesity drug VK2735. The company also has other promising programs in its pipeline.

5 Things You Need to Know If You Buy Viking Therapeutics Stock Today

Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.

Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data

Viking Therapeutics Inc.'s stock rose 1.9% early Wednesday to add to its prior-day gains, as analysts welcomed positive data from the company's early trial of an oral weight-loss treatment — the latest bullish announcement from the biotech.

Viking Therapeutics' positive results for oral weight-loss drug has analysts backing buy ratings

Given the pharmaceutical industry's assured success driven by innovation and the development of medications targeting diverse healthcare issues, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have emerged as dominant players, capturing significant market demand.

Missed out on Eli Lilly and Novo Nordisk? This pharma stock could be the next ‘big thing'

Viking Therapeutics (NASDAQ: VKTX ) stock is up on Tuesday as the company posts positive results from a short-term study of its weight loss drug. These results come from its Phase 1 study of VK2735.

Why Is Viking Therapeutics (VKTX) Stock Up 24% Today?

Viking Therapeutics Inc   (NASDAQ:VKTX) is skyrocketing today, last seen up 22.3% at $84.62.

Viking Therapeutics Stock Soars on Successful Trial

Viking stock gapped up Tuesday after the biotech company's oral weight-loss drug beat expectations in a 28-day study.

News for Viking Therapeutics Stock (VKTX)